Impact of Oral vs. Transdermal Oestrogen on Cortisol & CBG Before SST
NCT07928024, Completed, Norfolk and Norwich University Hospitals NHS Foundation Trust
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Impact of Oral vs. Transdermal Oestrogen on Cortisol & CBG Before SST | ClinicalTrials.gov |
| NCT number | NCT07928024 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 1 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Norfolk and Norwich University Hospitals NHS Foundation Trust | ClinicalTrials.gov |
| Conditions | Cortisol, Cortisol Binding Globulin | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in cortisol binding globulin (CBG) concentration and serum cortisol levels | 6 weeks | The primary outcome measures are the changes in cortisol binding globulin (CBG) concentration and serum cortisol levels over a six-week period following the discontinuation of oral or transdermal oestrogen therapy. These will be assessed through weekly blood samples, with additional comparison to salivary cortisol levels. The aim is to evaluate the impact of oestrogen route on CBG and cortisol levels, and to determine whether the current 6-week cessation period for oral oestrogen prior to the Short Synacthen Test (SST) can be safely shortened. This could improve test accuracy, patient experience, and potentially support the continued use of transdermal oestrogen without interruption. | ClinicalTrials.gov |
| Secondary | Salivary cortisol and cortisone levels | 6 weeks | Salivary cortisol and cortisone levels measured weekly over the 6-week period, to evaluate their potential as non-invasive alternatives to serum cortisol for assessing adrenal function. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)